



EPILEPSY FOUNDATION OF
VIRGINIA
PROMOTE AWARENESS
PROVIDE ASSISTANCE
WWW.EPILEPSYVA.COM

ILAE 2017 Classification of Seizure Types¹

Focal Onset Generalized Onset Unknown Onset

Aware Impaired
Aware-
ness

Motor Onset

- ♦ Automatisms
- ♦ Atonic²
- ♦ Clonic
- ♦ Epileptic spasms²
- ♦ Hyperkinetic
- ♦ Myoclonic
- ♦ Tonic

Non-Motor Onset

- ♦ Autonomic
- ♦ Behavior arrest
- ♦ Cognitive
- ♦ Emotional
- ♦ Sensory

Motor

- ♦ Tonic-clonic
- ♦ Clonic
- ♦ Tonic
- ♦ Myoclonic
- ♦ Myoclonic-tonic-clonic
- ♦ Myoclonic-atonic
- ♦ Atonic
- ♦ Epileptic Spasms

Non-Motor (Absence)

- ♦ Typical
- ♦ Atypical
- ♦ Myoclonic
- ♦ Eyelid Myoclonia

Motor

- ♦ Tonic-clonic
- ♦ Epileptic spasms

Non-Motor

- ♦ Behavior arrest

Unclassified³

¹Definitions, other seizure types and descriptors are listed in the accompanying paper and glossary of terms

²Degree of awareness usually is not specified

³Due to inadequate information or inability to place in other categories

Focal to bilateral tonic-clonic

NEWSLETTER

January 2017

Even though the names change, the first aid stays the same. Email srb3m@virginia.edu for more info .

Mark your calendar:
OCTOBER 14, 2017 EARLY MORNING

Tour de midnight
50 KM AND 100 KM bike rides to support the
EPILEPSY FOUNDATION of VIRGINIA

2410 Granite Ridge Rd, Rockville, VA 23146
Info: lcworth@hotmail.com or srb3m@virignia.edu

USE A HELMET
PREVENT EPILEPSY



15 December 2016 "EFVA Dine2Donate" held at Quaker Steak & Lube Restaurant in Newport News to promote Epilepsy Awareness and raise funds for EFVA.

Events organized by regional directors in Williamsburg and Northern Virginia.. Left: Dennis and Misty Terry below Gina Washington's event



Lawsuit Against Drug Manufacturer

Drug manufacturer Mallinckrodt Pharmaceuticals settled a lawsuit with the US Federal Trade Commission (FTC) for US\$100 million, for engaging in illegal anti-competitive behaviour to ensure its continued monopoly over a life-saving medication for infants with epilepsy.

More than a decade ago, Acthar Gel sold for \$40 a vial, but since it's been acquired by Mallinckrodt, the price has been raised to more than \$34,000 a vial, netting the company more than [\\$1 billion in revenue](#) in 2015.



USE A HELMET ART SELECTION COBINED WITH SUSAN J. GOODE MEMORIES IN CHARLOTTESVILLE. 35 VOTED ON THE KIDS' ART-

LEADERS OF AMERICA'S Drug Enforcement Administration have long demonstrated a shockingly casual relationship with facts and science on drug risks. The idea that marijuana — completely legal in several states and available for medical use in most — should be listed on the same Schedule 1 with heroin, bath salts and Ecstasy is the kind of laughable conclusion only a zealot could justify. The DEA is supposed to be a dispassionate law enforcement agency, doing its best to keep America safe. But when it wastes time, energy and money on the indefensible, it undermines the agency's very legitimacy . Take cannabidiol, commonly called CBD. Earlier this month, the DEA classified CBD, along with other marijuana derivatives, as Schedule 1 drugs, which means they have “no currently accepted medical use and a high potential for abuse.” Except that's simply not true. CBD — which doesn't impart the high of THC — has well-established medical uses.

According to a 2013 study published in the British Journal of Clinical Pharmacology, “CBD acts in some experimental models as an anti-inflammatory, anticonvulsant, anti-oxidant, anti-emetic, anxiolytic and anti-psychotic agent, and is therefore a potential medicine for the treatment of neuroinflammation, epilepsy, oxidative injury, vomiting and nausea, anxiety and schizophrenia, respectively.”

Want additional proof? Virginia's legislature in 2016 unanimously passed a bill authorizing a pharmaceutical processor to “manufacture and provide cannabidiol oil and THC-A oil to be used for the treatment of intractable epilepsy.” **HEAD ARTICLE VIRIGNIA PILOT DECEMBER 30, 2016**